DOCKET NO.: ISIS-4313



In Re Application of: Stanley T. Crook	Group Art Unit: 1635 Examiner: McGarry, S.
Serial No.: 09/479,783	Group Art Unit: 1635
Filing Date: January 7, 2000	Examiner: McGarry, S.
For: Oligoribonucleotides And Ribon	
	I HEREBY CERTIFY THAT THIS PAPER IS B DEPOSITED WITH THE UNITED STATES PO SERVICE AS FIRST CLASS MAIL, POSTAGE ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMIS FOR PATENTS, WASHINGTON, DC 20231.
	Paul K. Legaard REGISTRATION NO.: 38,534
Box SEQUENCE LISTINGS AF	
Assistant Commissioner for Patents Washington DC 20231	•
Sir:	
AMENDMENT	TRANSMITTAL LETTER
Transmitted herewith for filing in	the above-identified patent application is:
☐ A Preliminary Amendment.	
A Response to Notice to Comply	with Sequence Requirements and Prelimina
Amondment Bernansiye to the Office Ac	tion Dated September 14, 2001.
	the Paper filed

Appended Material as follows: \boxtimes Other Material as follows: Substitute pages 1 & 2 of Sequence Listing in paper and computer readable forms.

A copy of each reference as listed on the attached Form PTO-1449 is enclosed

Attached Form 1449.

herewith.

DOCKET NO.: ISIS-4313 -3- PATENT

FEE CALCULATION

No Additional Fee is Due.

******				SMALL	ENTITY	NOT SMAL	L ENTITY
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	24	24 (20 MINIMUM)	0	\$9 EACH	\$0	\$18 EACH	\$
INDEP. CLAIMS	6	6 (3 MINIMUM)	0	\$42 EACH	\$ 0	\$84 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT			\$140	\$0	\$280	\$	
☐ ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$
☐ TWO MONTH EXTENSION OF TIME			\$200	\$	\$400	\$	
☐ THREE MONTH EXTENSION OF TIME			\$460	\$	\$920	\$	
☐ FOUR MONTH EXTENSION OF TIME			\$720	\$	\$1440	\$	
☐ FIVE MONTH EXTENSION OF TIME			\$980	\$	\$1	\$	
☐ LESS ANY EXTENSION FEE ALREADY PAID			minus	(\$)	minus	(\$)	
☐ TERMINAL DISCLAIMER			\$55	\$	\$110	\$	
☐ OTHER FEE OR SURCHARGE AS FOLLOWS:							
	TOTAL	FEE DUE		*******	\$0	*************************************	\$

Ш	l A	Check	is Enclo	osed in	the ?	Foregoing	, Amount	Due.
---	-----	-------	----------	---------	-------	-----------	----------	------

Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of @@ to and through @@ comprising an extension of the shortened statutory period of @@ month(s).

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit

account 23-3050. This sheet is provided in duplicate.

X	refund	The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.				
		The Foregoing Amount Due for Filing this Paper.				
	\boxtimes	Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.				
	\boxtimes	Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).				

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: 2 OCTOBER 2001

Paul K. Legaard

Registration No. 38,534

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

c 2001 WW

DOCKET NO.: ISIS-4313

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Stanley T. Crooke

OCT 1 0 2001 TECH CENTER 1600/2900

Serial No.: 09/479,783

Group Art Unit: 1635

Examiner: McGarry, S.

Filing Date: January 7, 2000

Oligoribonucleotides And Ribonucleases For Cleaving RNA

DATE OF DEPOSIT: October 2, 2001 I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO BOX SEQUENCE, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

Paul K. Legaard

REGISTRATION NO.: 38,534

BOX SEQUENCE

Assistant Commissioner for Patents Washington DC 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

In response to the "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated September 14, 2001, a response to which is due October 14, 2001, enclosed herewith is:

- Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 \boxtimes through 1.825;
- \boxtimes Substitute pages of the Sequence Listing;
- Substitute copy of the computer readable form of amended Sequence Listing; \boxtimes
- Copy of Notice to Comply With Requirements for Patent Applications \boxtimes Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;

DOCKET N	O.: ISIS-4313	- 2 -	PATENT	
	Petition for Extension of Time	; ;		
	Other:			
The Commissioner is hereby authorized to charge any underpayment associated with this				
communicat	ion or credit any overpayment	to Deposit Account No. 23-3050.	This sheet is	
attached in d	uplicate.			
Date: 20	CTOBER 2001	Paul K. Legaard Registration No. 38,534	<u> </u>	

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2001 WW

NO∯CE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of Sequence Listing as required by 37 C.F.R. 1.821(e).
	7.	Other:
Аp	pΙ	icant Must Provide:
X	Α	n initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X		n initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry to the specification.
X	a	statement that the content of the paper and computer readable copies are the same and, where oplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 825(b) or 1.825(d).
Foi	· q	uestions regarding compliance to these requirements, please contact:
Foi	er	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 otln Software Program Support
		Fechnical Assistance703-287-0200 To Purchase PatentIn Software703-306-2600
		PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY